Implications of hepatitis B virus genomic variations on treatment outcomes

Current Pharmacogenomics and Personalized Medicine

Volumn 8, Issue 4, 2010, Pages 280-288

  Tseng, Tai Chung ^a   Liu, Chun Jen ^b   Kao, Jia Horng ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Basal core promoter; Genotype; Hepatitis b e antigen seroconversion; Lamivudine; Pegylated interferon; Precore stop codon

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA HYBRIDIZATION; ENZYME BLOOD LEVEL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); MOLECULAR CLONING; NONHUMAN; NONSENSE MUTATION; PROMOTER REGION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD; VIRUS MUTANT; VIRUS STRAIN;

EID: 84863115768     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569210793368195     Document Type: Review

References (81)

1. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262(5132): 369-70.
2. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46(6): 400-7.
3. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373(9663): 582-92.
4. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-93.
5. Hunt CM, McGill JM, Allen MI, et al. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31(5): 1037-44.
6. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118-29.
7. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007; 1(4): 415-30.
8. Liaw YF, Lau GK, Kao JH, et al. Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection. Dig Dis Sci 2010 Mar 18. [Epub ahead of print].
9. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50(2): 227-42.
10. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2(3): 263-283.
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45(2): 507-39.
12. Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol 2008; 82(11): 5657-63.
13. Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 2008; 14(11): 1777-80.
14. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83(20): 10538-47.
15. Kao JH, Chen PJ, Lai MY, et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40(4): 1207-9.
16. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(16): 1134-43.
17. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33(6): 998-1002.
18. Liu CJ, Lai MY, Chao YC, et al. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43(4): 742-9.
19. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36(6): 1425-30.
20. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54(7): 1009-13.
21. Zhang X, Zoulim F, Habersetzer F, et al. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48(1): 8-16.
22. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682-95.
23. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomised trial. Lancet 2005; 365(9454): 123-9.
24. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137(6): 2002-9.
25. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitisB e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44(4): 541-8.
26. Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46(2): 388-94.
27. Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006; 101(11): 2523-9.
28. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135(2): 459-67.
29. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut 2007; 56(5): 699-705.
30. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15(46): 5761-9.
31. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36(2): 303-4.
32. Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39(1): 42-50.
33. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38(5): 1267-73.
34. Akuta N, Suzuki F, Kobayashi M, et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38(3): 315-21.
35. Zollner B, Petersen J, Schroter M, et al. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 2001; 357(9260): 934-5.
36. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8(6): 531-4.
37. Liu CJ, Huang WL, Chen PJ, et al. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10(24): 3574-8.
38. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19(11): 1276-82.
39. Zollner B, Petersen J, Schafer P, et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002; 34(9): 1273-7.
40. Kuwahara R, Kumashiro R, Murashima S, et al. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J Med Virol 2004; 72(1): 26-34
41. Suzuki F, Tsubota A, Arase Y, et al. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003; 46(3): 182-9.
42. Tseng TC, Liu CJ, Wang CC, et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009; 14(2): 203-10.
43. Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36(3): 445-6.
44. Hsieh TH, Tseng TC, Liu CJ, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009; 14(8): 1157-63.
45. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125(1): 107-16.
46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131(6): 1743-51.
47. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51(1): 11-20.
48. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136(2): 486-95.
49. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48(1): 99-108.
50. Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124(2): 327-34.
51. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006; 193(9): 1258-65.
52. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B virus precore/ core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006; 194(5): 594-9.
53. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2(8663): 588-91.
54. Okamoto H, Yotsumoto S, Akahane Y, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64(3): 1298-303.
55. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68(12): 8102-10.
56. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995; 21(1): 19-24.
57. Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31(3): 716-25.
58. Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79(8): 1055-63.
59. Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46(2): 117-23.
60. Thompson AJ, Ayres A, Yuen L, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007; 22(7): 1078-85.
61. Asahina Y, Izumi N, Uchihara M, et al. Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol 2003; 39(6): 1063-9.
62. Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007; 133(3): 951-8.
63. Kanai K, Kako M, Aikawa T, et al. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Am J Gastroenterol 1996; 91(10): 2150-6.
64. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008; 13(5): 613-24.
65. Chen PJ, Lin CG, Lin FY, et al. Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients. J Hum Genet 2006; 51(11): 984-91.
66. King JK, Yeh SH, Lin MW, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002; 36(6): 1416-24.
67. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.
68. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138(4): 1338-45, 1345 e1-7.
69. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41(10): 1100-4.
70. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461(7265): 798-801.
71. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41(5): 591-5.
72. Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105(3): 845-50.
73. Kako M, Kanai K, Aikawa T, et al. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B. J Clin Gastroenterol 1997; 25(2): 440-5.
74. Chen CH, Lee CM, Lu SN, et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006; 44(1): 76-82.
75. Yuen MF, Sablon E, Libbrecht E, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther 2006; 11(6): 779-86.
76. Fukai K, Zhang KY, Imazeki F, et al. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase. J Viral Hepat 2007; 14(9): 661-6.
77. Aikawa T, Kanai K, Kako M, et al. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody:comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepat 1995; 2(5): 243-50.
78. Shindo M, Hamada K, Koya S, et al. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94(8): 2237-45.
79. Marrone A, Zampino R, Luongo G, et al. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46(4): 222-6.
80. Hannoun C, Horal P, Krogsgaard K, et al. Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B. J Med Virol 2002; 66(2): 171-8.
81. Liu CJ, Chen PJ, Lai MY, et al. Lack of interferon sensitivitydetermining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9(6): 895-903.